THOMSON REUTERS
CORTELLIS™

CoNCERT Pharmaceuticals Inc

CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 14-Dec-2014

THOMSON REUTERS
3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

Return to Table of Contents

THOMSON REUTERS

ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurateand validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

Return to Table of Contents

GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Return to Table of Contents

TABLE OF CONTENTS

Return to Table of Contents

CoNCERT Pharmaceuticals Inc

COMPANY OVERVIEW

Company Name	CoNCERT Pharmaceuticals Inc
Parent Company Name	CoNCERT Pharmaceuticals Inc
Website	http://www.concertpharma.com/
Country	US
Number of Drugs in Active Development	7
Number of Inactive Drugs	17
Number of Patents as Owner	161
Number of Patents as Third Party	1
Number of Deals	8
Key Indications	Neuropathic pain,Epilepsy,Renal disease,Inflammatory disease,Pain,Cancer,Multiple myeloma,Cystic fibrosis,Anxiety disorder,Brain
Key Target-based Actions	NMDA receptor antagonist,GABA A receptor modulator,GABA B receptor agonist,CFTR stimulator,Calcium channel inhibitor T-type,PDE inhibitor,HIV protease inhibitor,Opioid receptor sigma agonist 1,Sigma opioid receptor agonist,Cytochrome P450 2D6 inhibitor,HIV-1 protease inhibitor
Key Technologies	Small molecule therapeutic,Oral formulation,Drug combination,Formulation preservation,Antibiotic,Capsule formulation,Controlled release formulation,Suspension,Crystalline form,Prodrug

COMPANY PROFILE

SUMMARY

CoNCERT Pharmaceuticals Inc is a Boston-based pharmaceutical company which uses chemical methodology, involving an innovative precision deuterium chemistry platform to modify specific properties of validated drug molecules, to create bioavailable drug candidates.

EARLY R&D

By May 2009, Concert Pharmaceuticals was investigating deuterium analogs of rimonabant and mosapride.

By January 2008, the company was researching an HER2/EGFR inhibitor, an antiviral, a cytokine inhibitor and a number of antibiotics, for deuteration. By June 2008, CoNCERT was also researching a protease inhibitor for the potential treatment of HIV, an antifibrotic agent, an NMDA antagonist/ sigma agonist for the potential treatment of neuropathic pain, an antibacterial for the potential treatment of MRSA, an antipsychotic for the potential treatment for schizophrenia, a PDE-5 inhibitor for the potential treatment pulmonary arterial hypertension and benign prostate hyperplasia, a calcium modulator for the potential treatment of hyperparathyroidism, an EGFR inhibitor for the potential treatment of tumors and a CCR5 antagonist for the potential treatment of HIV.

FINANCIAL

In February 2014, CoNCERT priced a planned IPO of its common stock at $14 per share. Underwriters would be granted a 30-day option to purchase up to an additional 900,000 shares at the same price to cover overallotments. The shares would trade on the NASDAQ Global Market under the ticker symbol 'CNCE'. At that time, the offering was expected to close on February 19, 2014. Later that month, the offering was closed; in March 2014, underwriters exercised their over-allotment option and purchased an additional 649,690 shares which increased a capital raise of approximately $93 million; at that time, net proceeds of $83.1 million was raised.

In April 2008, CoNCERT Pharmaceuticals raised $37 million in a series C financing round. The company planned to use the funds to advance its deuterium chemistry platform and product pipeline.

In November 2006, CoNCERT raised $48.5 million in series B financing.

In July 2006, CoNCERT raised $10 million from a series A venture capital financing.

Return to Table of Contents

PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart



Return to Table of Contents

Drugs by Indication Table

Indication	Active	Inactive	Total
Neurological disease	2	5	7
Infectious disease	1	5	6
Cardiovascular disease	1	4	5
Inflammatory disease	1	3	4
Neoplasm	0	4	4
Psychiatric disorder	0	3	3
Musculoskeletal disease	1	2	3
Genitourinary disease	1	1	2
Gastrointestinal disease	1	1	2
Respiratory disease	1	1	2
Immune disorder	0	2	2
Hematological disease	0	1	1
Injury	1	0	1

Drugs by Highest Status

Active Drugs by Highest Status Chart



Return to Table of Contents

Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	1
Phase 1 Clinical	3
Discovery	3
Discontinued	2
No Development Reported	15

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Screening/Evaluation	1	0	1	0	2
Drug - Development/Commercialization License	4	0	0	0	4
Drug - CRADA	1	0	0	0	1
Drug - Funding	1	0	0	0	1

CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Genitourinary disease	0	3
Infectious disease	0	1
Cardiovascular disease	0	1
Psychiatric disorder	0	1

Trials by Phase

Phase	Ongoing	All
Phase 3	0	1
Phase 2	0	1
Phase 1	0	11

Phase Definitions

Phase 3 Clinical
Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Return to Table of Contents

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

Indication	As Owner	As Third Party	Total
Cardiovascular disease	61	0	61
Endocrine disease	46	0	46
Gastrointestinal disease	71	0	71
Genitourinary disease	65	0	65
Growth disorder	11	0	11
Hematological disease	35	0	35
Degeneration	14	0	14
Andrology	22	0	22
Immune disorder	57	0	57
Psychiatric disorder	33	0	33
Musculoskeletal disease	30	0	30
Neoplasm	55	0	55
Ocular disease	18	0	18
Genetic disorder	19	0	19
Metabolic disorder	41	0	41
Mouth disease	1	0	1
Neurological disease	80	0	80
Nutritional disorder	16	0	16
Respiratory disease	35	0	35
Infectious disease	41	0	41
Injury	6	0	6
Toxicity and intoxication	12	0	12
Inflammatory disease	47	0	47

Return to Table of Contents

Fatigue	3	0	3
Otorhinolaryngological disease	3	0	3
Gynecology and obstetrics	24	0	24
Dermatological disease	32	0	32
Ulcer	5	0	5

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Return to Table of Contents

PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

CTP-499

CTP-499 SNAPSHOT

Drug Name	CTP-499
Key Synonyms	
Originator Company	CoNCERT Pharmaceuticals Inc
Active Companies	GlaxoSmithKline plc;CoNCERT Pharmaceuticals Inc
Inactive Companies	
Highest Status	Phase 2 Clinical
Active Indications	Renal disease
Target-based Actions	PDE inhibitor
Other Actions	Antioxidant agent;Renal system agent;Fibrosuppressant;Anti-inflammatory
Technologies	Oral formulation;Controlled release formulation;Small molecule therapeutic
Last Change Date	10-Dec-2014

CTP-499 DEVELOPMENT PROFILE

SUMMARY

CoNCERT, in collaboration with GlaxoSmithKline (GSK), is developing CTP-499, a controlled release, deuterated analog of 1-((S)-5-hydroxyhexyl)-3,7-dimethylxanthine (HDX), which is an active metabolite (M1) of pentoxifylline (PTX) that acts as an anti-inflammatory/antioxidant/antifibrotic agent/PDE inhibitor, created using CoNCERT's deuterated chemical entity platform, for the potential oral treatment of type 2 diabetic nephropathy and other forms of chronic kidney diseases (CKD),,,. In February 2012, a phase II type 2 diabetic nephropathy trial began ; in April 2014, results were presented. In January 2014, the drug was listed as being in phase II development. In July 2014, the company planned to submit a request for a Special Protocol Assessment (SPA) to the FDA, later that year. In November 2014, the company planned to initiate a SPA discussion with the US FDA by the end of 2014 for potential future phase III development of CTP-499. In October 2011, CoNCERT was seeking to outlicense the drug.

CTP-499 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
CoNCERT Pharmaceuticals Inc	Renal disease	US	Phase 2 Clinical	08-Feb-2012
GlaxoSmithKline plc	Renal disease	US	Discovery	02-Jun-2009

Return to Table of Contents

CTP-499 DRUG NAMES

Names	Type
CTP-499	Research Code
deuterated undisclosed antiflammatory/antioxidant/antifibrotic agent (controlled release formulation, chronic kidney disease), CoNCERT/GSK	
deuterated analog of 1-((S)-5-hydroxyhexyl)-3,7-dimethylxanthine (HDX) (controlled release formulation, chronic kidney disease), CoNCERT/GSK	

CTP-499 CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
End stage renal disease											
0	0	0	0	0	0	0	1	0	0	0	1
Renal disease											
0	0	0	0	0	0	0	1	0	0	0	1
Diabetic nephropathy											
0	0	0	0	0	1	0	0	0	0	0	1

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	1	0	2	0	0	0	3

Phase Definitions

Phase 3 Clinical
Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical
Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical
Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

Return to Table of Contents

CTP-499 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
CoNCERT Pharmaceuticals Inc	1	0	0	0	1
GlaxoSmithKline plc	0	0	1	0	1

Return to Table of Contents

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

Return to Table of Contents

PATENTS

Patents by Parent Company Chart



Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
CoNCERT Pharmaceuticals Inc	2	0	2
GlaxoSmithKline plc	1	0	1

Return to Table of Contents

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
Product (derivative)	1
Product	1

Return to Table of Contents

CTP-347

CTP-347 SNAPSHOT

Drug Name	CTP-347
Key Synonyms	
Originator Company	CoNCERT Pharmaceuticals Inc
Active Companies	CoNCERT Pharmaceuticals Inc
Inactive Companies	
Highest Status	Phase 1 Clinical
Active Indications	Hot flashes
Target-based Actions	
Other Actions	5-HT uptake inhibitor
Technologies	Oral formulation;Small molecule therapeutic
Last Change Date	09-Apr-2014

CTP-347 DEVELOPMENT PROFILE

SUMMARY

CoNCERT is developing CTP-347, a deuterated form of the selective serotonin reuptake inhibitor paroxetine, for the potential oral treatment of vasomotor symptoms such as hot flashes,. In September 2008, a phase I trial for hot flashes began ; data from the trial were reported in September 2009. In October 2011, the drug was still listed as being in phase I development ; in March 2014, this was still the case. In October 2011, the company was seeking to outlicense the drug.

CTP-347 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
CoNCERT Pharmaceuticals Inc	Hot flashes	US	Phase 1 Clinical	25-Sep-2008

CTP-347 CHEMICAL STRUCTURES

Return to Table of Contents

CAS Registry Number:	Confidence Level:
	4



Name	Type
CTP-347	Research Code

CTP-347 DRUG NAMES

Names	Type
CTP-347	Research Code
deuterated paroxetine (oral, vasomotor symptoms), CoNCERT	

CTP-347 CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Hot flashes											
0	0	0	0	0	0	0	1	0	0	0	1

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	0	0	1	0	0	0	1

Phase Definitions

Phase 3 Clinical
Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Return to Table of Contents

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

CTP-347 DEALS AND PATENTS

PATENTS

Patents by Parent Company Chart



Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
CoNCERT Pharmaceuticals Inc	2	0	2

Return to Table of Contents

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
Product	2
Process	1

Return to Table of Contents

CTP-730

CTP-730 SNAPSHOT

Drug Name	CTP-730
Key Synonyms	
Originator Company	CoNCERT Pharmaceuticals Inc
Active Companies	CoNCERT Pharmaceuticals Inc;Celgene Corp
Inactive Companies	
Highest Status	Phase 1 Clinical
Active Indications	Inflammatory disease
Target-based Actions	
Other Actions	Anti-inflammatory;Anticancer;Unspecified drug target
Technologies	Oral formulation;Suspension;Small molecule therapeutic
Last Change Date	13-Nov-2014

CTP-730 DEVELOPMENT PROFILE

SUMMARY

CoNCERT Pharmaceuticals, in collaboration with Celgene Corp, is developing CTP-730, a lead from deuterium-modified compounds, using the company's deuterated chemical entity platform (DCE) technology, for the potential treatment of inflammation. In September 2014, a phase I trial was initiated. At that time, the trial was expected to complete in 2015. In November 2014, the multiple ascending dose phase I trial was expected to begin in 2015.

CoNCERT Pharmaceuticals, in collaboration with Celgene Corp was previously investigating deuterium-modified compounds, using the company's deuterated chemical entity platform (DCE) technology, for the potential treatment of cancer. In November 2013, the drug was listed as being in preclinical development ; however by January 2014, the program was no longer developed for the treatment of cancer.

CLINICAL DATAPHASE I

In January 2014, phase I trials were planned for that year. In May 2014, the company was planning to initiate clinical trials by the end of 2014. In September 2014, a randomized, interventional, double-blind, single ascending, safety, tolerability and pharmacokinetics phase I trial (NCT02239081; CP730.1001) of CTP-730 was initiated in healthy subjects (expected n = 40) in Australia. At that time, the trial was expected to complete in 2015. In November 2014, the multiple ascending dose phase I trial was expected to begin in 2015.

CTP-730 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date

Return to Table of Contents

Company	Indication	Country	Development Status	Date
Celgene Corp	Inflammatory disease	US	Phase 1 Clinical	10-Sep-2014
CoNCERT Pharmaceuticals Inc	Inflammatory disease	US	Phase 1 Clinical	10-Sep-2014
Celgene Corp	Cancer	US	No Development Reported	30-Jan-2014
CoNCERT Pharmaceuticals Inc	Cancer	US	No Development Reported	30-Jan-2014

CTP-730 DRUG NAMES

Names	Type
CTP-730	Research Code
deuterium-modified compounds (cancer/inflammation), CoNCERT/Celgene	

CTP-730 CLINICAL TRIALS

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	0	0	1	0	0	0	1

Return to Table of Contents

CTP-730 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
CoNCERT Pharmaceuticals Inc	1	0	0	0	1
Celgene Corp	0	0	1	0	1

Return to Table of Contents

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

Return to Table of Contents

CTP-354

CTP-354 SNAPSHOT

Drug Name	CTP-354
Key Synonyms	
Originator Company	CoNCERT Pharmaceuticals Inc
Active Companies	CoNCERT Pharmaceuticals Inc
Inactive Companies	
Highest Status	Phase 1 Clinical
Active Indications	Neuropathic pain;Muscle hypertonia
Target-based Actions	GABA A receptor modulator
Other Actions	Analgesic;Anxiolytic
Technologies	Oral formulation;Small molecule therapeutic
Last Change Date	13-Nov-2014

CTP-354 DEVELOPMENT PROFILE

SUMMARY

CoNCERT Pharmaceuticals is developing CTP-354 (C-21191), the lead from deuterium-modified, non-sedating subtype-selective GABA A modulators using its deuterated chemical entity (DCE) platform, for the potential oral treatment of spasticity and neuropathic pain ,. In March 2013, the drug was listed as being in phase I development. By March 2014, a multiple-ascending dose phase I study had been initiated. In July 2014, the US FDA lifted a partial clinical hold on the phase I spasticity study ; in August 2014, positive results were reported. In October 2014, positive results were reported and at that time, the company planned to initiate phase II trials for spasticity associated with spinal cord injury and multiple sclerosis by the end of 2014 and in 'early 2015', respectively. In November 2014, the company announced the delay in the initiation of phase II trials and planned to conduct additional non-clinical studies prior to advancing into phase II trials. In March 2013, the company was seeking to outlicense the drug.

The company was previopusly investigating the drug for the potential treatment of anxiety ,; however, no further development had been reported for this indication.

CTP-354 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
CoNCERT Pharmaceuticals Inc	Muscle hypertonia	US	Phase 1 Clinical	13-Mar-2013
CoNCERT Pharmaceuticals Inc	Neuropathic pain	US	Phase 1 Clinical	13-Mar-2013
CoNCERT Pharmaceuticals Inc	Anxiety disorder	US	No Development Reported	14-Mar-2013

Return to Table of Contents

CTP-354 DRUG NAMES

Names	Type
deuterium-modified GABA-A modulator (spasticity/neuropathic pain/anxiety), CoNCERT Pharmaceuticals	
C-21191	Research Code
CTP-354	Research Code

CTP-354 CLINICAL TRIALS

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	0	0	2	0	0	0	2

CTP-354 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



Return to Table of Contents

Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
CoNCERT Pharmaceuticals Inc	1	0	0	0	1
National Multiple Sclerosis Society	0	0	1	0	1

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Funding	1	0	1

Return to Table of Contents

C-10068

C-10068 SNAPSHOT

Drug Name	C-10068
Key Synonyms	
Originator Company	CoNCERT Pharmaceuticals Inc
Active Companies	Walter Reed Army Institute of Research;CoNCERT Pharmaceuticals Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Epilepsy;Neuropathic pain;Brain injury
Target-based Actions	Opioid receptor sigma agonist 1
Other Actions	Antidepressant;Analgesic;Neuroprotectant;Anticonvulsant agent
Technologies	Oral formulation;Small molecule therapeutic
Last Change Date	15-May-2014

C-10068 DEVELOPMENT PROFILE

SUMMARY

CoNCERT Pharmaceuticals and the Walter Reed Army Institute of Research (WRAIR) are investigating C-10068, the lead from deuterium-modified sigma-1 agonists, for the potential oral treatment of neuropathic pain, epilepsy and other seizure-generating diseases and injuries such as ischemic stroke and traumatic brain injury (TBI),. By February 2011, development was ongoing . In September 2012, the drug was listed as being in research for epilepsy. In January 2014, the drug was listed as being in preclinical development for pain and seizures. In May 2014, the company was planning to initiate clinical trials by the end of 2014. In October 2011, the company was seeking to outlicense the drug.

CoNCERT and WRAIR were previously investigating the drug for the potential treatment of depression. In September 2012, the drug was listed as being in research for epilepsy and depression ; however, in January 2014, the drug was no longer being investigated for depression.

C-10068 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
CoNCERT Pharmaceuticals Inc	Brain injury	US	Discovery	02-Feb-2011
CoNCERT Pharmaceuticals Inc	Epilepsy	US	Discovery	02-Feb-2011
CoNCERT Pharmaceuticals Inc	Neuropathic pain	US	Discovery	02-May-2011
Walter Reed Army Institute of Research	Brain injury	US	Discovery	02-Feb-2011

Return to Table of Contents

Company	Indication	Country	Development Status	Date
Walter Reed Army Institute of Research	Epilepsy	US	Discovery	02-Feb-2011
Walter Reed Army Institute of Research	Neuropathic pain	US	Discovery	02-May-2011
CoNCERT Pharmaceuticals Inc	Depression	US	No Development Reported	31-Jan-2014
Walter Reed Army Institute of Research	Depression	US	No Development Reported	31-Jan-2014

C-10068 DRUG NAMES

Names	Type
deuterated sigma-1 agonists (epilepsy/brain injury/neuropathic pain), CoNCERT/Walter Reed Army Institute	
C-10068	Research Code
deuterium-modified sigma-1 agonist (epilepsy/depression), CoNCERT	

C-10068 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



Return to Table of Contents

Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
CoNCERT Pharmaceuticals Inc	1	0	1	0	2
US Government	1	0	1	0	2

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - CRADA	1	0	1
Drug - Screening/Evaluation	1	0	1

Return to Table of Contents

PATENTS

Patents by Parent Company Chart



Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
CoNCERT Pharmaceuticals Inc	1	0	1

Patents by Drug Relationship Type Chart



Return to Table of Contents

Patents by Drug Relationship Type Table

Drug Relationship	Total
Tentative	1

Return to Table of Contents

deuterated praziquantel analogs (schistosomiasis), Therapeutics for Rare and Neglected Diseases/CoNCERT Pharmaceuticals

deuterated praziquantel analogs (schistosomiasis), Therapeutics for Rare and Neglected Diseases/CoNCERT Pharmaceuticals SNAPSHOT

Drug Name	deuterated praziquantel analogs (schistosomiasis), Therapeutics for Rare and Neglected Diseases/CoNCERT Pharmaceuticals
Key Synonyms	
Originator Company	CoNCERT Pharmaceuticals Inc
Active Companies	Therapeutics for Rare and Neglected Diseases;CoNCERT Pharmaceuticals Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Schistosomiasis
Target-based Actions	
Other Actions	Unspecified drug target;Antiparasitic
Technologies	Small molecule therapeutic
Last Change Date	04-Sep-2014

deuterated praziquantel analogs (schistosomiasis), Therapeutics for Rare and Neglected Diseases/CoNCERT Pharmaceuticals DEVELOPMENT PROFILE

SUMMARY

Therapeutics for Rare and Neglected Diseases and CoNCERT Pharmaceuticals, are investigating deuterium-modified praziquantel analogs for the potential treatment for schistosomiasis. In February 2013, preclinical studies were ongoing ; in August 2014, this was still the case.

deuterated praziquantel analogs (schistosomiasis), Therapeutics for Rare and Neglected Diseases/CoNCERT Pharmaceuticals DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
CoNCERT Pharmaceuticals Inc	Schistosomiasis	US	Discovery	15-Nov-2011
Therapeutics for Rare and Neglected Diseases	Schistosomiasis	US	Discovery	01-Feb-2013

deuterated praziquantel analogs (schistosomiasis), Therapeutics for Rare and Neglected Diseases/CoNCERT Pharmaceuticals DRUG NAMES

Names	Type
deuterated praziquantel analogs (schistosomiasis), CoNCERT Pharmaceuticals	
deuterated praziquantel analogs (schistosomiasis), Therapeutics for Rare and Neglected Diseases/CoNCERT Pharmaceuticals	

Return to Table of Contents

DEALS

Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
CoNCERT Pharmaceuticals Inc	1	0	0	0	1
US Government	0	0	1	0	1

Return to Table of Contents

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Screening/Evaluation	1	0	1

Return to Table of Contents

deuterated ivacaftor analogs (cystic fibrosis/COPD), Concert Pharmaceuticals

deuterated ivacaftor analogs (cystic fibrosis/COPD), Concert Pharmaceuticals SNAPSHOT

Drug Name	deuterated ivacaftor analogs (cystic fibrosis/COPD), Concert Pharmaceuticals
Key Synonyms	
Originator Company	CoNCERT Pharmaceuticals Inc
Active Companies	CoNCERT Pharmaceuticals Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cystic fibrosis;Chronic obstructive pulmonary disease
Target-based Actions	CFTR stimulator
Other Actions	
Technologies	Oral formulation;Small molecule therapeutic
Last Change Date	15-May-2014

deuterated ivacaftor analogs (cystic fibrosis/COPD), Concert Pharmaceuticals DEVELOPMENT PROFILE

SUMMARY

CoNCERT Pharmaceuticals is investigating deuterated ivacaftor analogs as potentiators of cystic fibrosis transmembrane conductance regulator, for the potential oral treatment of cystic fibrosis and COPD,. In September 2013, preclinical data were presented. In May 2014, the company was planning to initiate clinical trials by the end of 2014. In November 2013, the company was seeking to outlicense the drug.

deuterated ivacaftor analogs (cystic fibrosis/COPD), Concert Pharmaceuticals DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
CoNCERT Pharmaceuticals Inc	Chronic obstructive pulmonary disease	US	Discovery	14-Mar-2013
CoNCERT Pharmaceuticals Inc	Cystic fibrosis	US	Discovery	14-Mar-2013

deuterated ivacaftor analogs (cystic fibrosis/COPD), Concert Pharmaceuticals CHEMICAL STRUCTURES

Return to Table of Contents

CAS Registry Number:	Confidence Level:
	4



deuterated ivacaftor analogs (cystic fibrosis/COPD), Concert Pharmaceuticals DRUG NAMES

Names	Type
deuterated ivacaftor analogs (cystic fibrosis/COPD), Concert Pharmaceuticals	

deuterated ivacaftor analogs (cystic fibrosis/COPD), Concert Pharmaceuticals DEALS AND PATENTS

PATENTS

Patents by Parent Company Chart



Return to Table of Contents

Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
CoNCERT Pharmaceuticals Inc	3	0	3

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
Tentative	3

Return to Table of Contents

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:
http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

Return to Table of Contents